Results 121 to 130 of about 51,741 (305)

Systemic reactogenicity following homologues and heterologous prime-boost AZD1222 and BNT162b2 COVID-19 vaccination of 2862 healthcare workers compared with an unvaccinated population

open access: yesVaccine: X, 2023
During spring 2021, AZD1222 and BNT162b2 were used as prime and BNT162b2 as booster COVID-19 vaccines in Denmark. We obtained self-reported information on systemic reactogenicity day-by-day during two weeks for 2862 healthcare workers vaccinated with ...
Sorosh Tabatabaeifar   +6 more
doaj   +1 more source

Nanoparticle Adjuvant Design Enhances Germinal Center Responses Targeting Conserved Subdominant Epitopes for Pan‐Coronavirus Vaccine Development

open access: yesAdvanced Science, EarlyView.
Current SARS‐CoV‐2 vaccines generate short‐lived, strain‐specific immunity. A polymeric TLR7 agonist nanoparticle (TLR7‐NP) adjuvant enhances lymph node targeting and promotes early and sustained germinal center responses toward conserved S2 epitopes of the spike protein.
Sijin Huang   +12 more
wiley   +1 more source

COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study [PDF]

open access: yes, 2022
Background: With the surge of new SARS-CoV-2 variants, countries have begun offering COVID-19 vaccine booster doses to high-risk groups and, more recently, to the adult population in general. However, uncertainty remains over how long primary vaccination
Capdevila J   +10 more
core   +1 more source

Impact of COVID‐19 and Vaccination on Lower Urinary Tract Symptoms: Insights From a Prospective Cohort Study

open access: yesNeurourology and Urodynamics, EarlyView.
ABSTRACT Aims To evaluate the prevalence, clinical course, and risk factors of lower urinary tract symptoms (LUTS) in patients hospitalized with COVID‐19, and to assess associations with comorbidities, disease severity, and vaccination status. Methods We conducted a prospective cohort study of adult patients hospitalized with confirmed COVID‐19, who ...
Julia Duarte de Souza   +12 more
wiley   +1 more source

BNT162b2 COVID-19 Vaccine Induced Immune Thrombocytopenic Purpura

open access: yesCase Reports in Medicine, 2022
Immune thrombocytopenic purpura (ITP) has been reported following vaccinations such as MMR as well as after viral infections such as hepatitis C and HIV. Few case reports have been reported of ITP after COVID-19 infections and COVID-19 vaccines. Herein, we present a patient who presented with severe ITP with a platelet count of 0 after receiving the ...
A. K. Ghosh   +5 more
openaire   +3 more sources

Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. [PDF]

open access: yes, 2021
ObjectiveTo assess the association between covid-19 vaccines and risk of thrombocytopenia and thromboembolic events in England among adults.DesignSelf-controlled case series study using national data on covid-19 vaccination and hospital admissions ...
Coupland, Carol A C   +13 more
core   +7 more sources

Vaccinations During Pregnancy Protect the Mother–Infant Dyad and Are Generally Safe

open access: yesActa Paediatrica, EarlyView.
ABSTRACT Aim Vaccination in pregnancy has a critical impact on mothers, foetuses and infants. The aim of this paper was to summarise key points presented by experts attending the 12th Maria Delivoria‐Papadopoulos Perinatal Symposium in March 2025 and further expand and update them.
Ariadne Malamitsi‐Puchner   +2 more
wiley   +1 more source

Keratoplasty Rejection After the BNT162b2 messenger RNA Vaccine

open access: yesCornea, 2021
Purpose: The aim of this report was to report 2 patients who presented with acute corneal graft rejection 2 weeks after receiving the BNT162b2 messenger RNA (mRNA) vaccine for severe acute respiratory syndrome coronavirus 2.
Lauren M, Wasser   +4 more
openaire   +3 more sources

Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine

open access: yesNew England Journal of Medicine, 2022
Background Active immunization with the BNT162b2 vaccine (Pfizer–BioNTech) has been a critical mitigation tool against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during the coronavirus disease 2019 (Covid-19) pandemic.
E. Moreira   +31 more
semanticscholar   +1 more source

The effectiveness and safety of mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines among individuals with chronic kidney diseases [PDF]

open access: yes, 2022
The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has posed a serious threat to individuals with underlying chronic kidney disease (CKD).
Chan, EWY   +9 more
core  

Home - About - Disclaimer - Privacy